This is consistent with the development of tumor-specific immunologic memory following PIC + RT + anti-CTLA-4 treatment and demonstrates the achievement of an enhanced in situ vaccine effect in these mice compared to that achieved with RT + anti-CTLA-4. This evidence concerns the gene CTLA4 and neoplasm.